David Ungar

David Ungar

Company: ADC Therapeutics

Job title: Head of US Oncology Clinical Development


Pre-clinical & Clinical Development of the First Approved PBD Based ADC 10:00 am

• Introduction to Zynlonta and its mode of action • Clinical data for Zynlonta approval as a monotherapy in r/r DLBCL • Lifecycle plansRead more

day: day 1 opps
day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.